Hepato-Pancreato-Biliary and Transplant Unit, Fondazione Policlinico Tor Vergata, Rome, Italy.
University of Rome Tor Vergata, Department of Surgical Science, Italy.
Best Pract Res Clin Gastroenterol. 2021 Oct-Dec;54-55:101770. doi: 10.1016/j.bpg.2021.101770. Epub 2021 Oct 14.
Life-long immunosuppression has always been considered the key in managing liver graft protection from recipient rejection. However, it is associated with severe adverse effects that lead to increased morbidity and mortality, including infections, cardiovascular diseases, kidney failure, metabolic disorders and de novo malignancies. This explains the great interest that has developed in the concept of tolerance in recent years. The liver, thanks to its marked tolerogenicity, is to be considered a privileged organ: up to 60% of selected patients undergoing liver transplantation could safely withdraw immunosuppression.
终身免疫抑制一直被认为是管理肝脏移植物免受受体排斥的关键。然而,它与严重的不良反应有关,导致发病率和死亡率增加,包括感染、心血管疾病、肾衰竭、代谢紊乱和新发性恶性肿瘤。这解释了近年来人们对耐受概念的极大兴趣。肝脏由于其显著的耐受性,被认为是一种特权器官:多达 60%的接受肝移植的选定患者可以安全地停止免疫抑制。